{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:20:34Z","timestamp":1779236434957,"version":"3.51.4"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T00:00:00Z","timestamp":1665014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Liver transplantation (LT) is considered a therapeutic option for unresectable perihilar cholangiocarcinoma (PHC) within defined criteria. It remains uncertain whether patients can safely receive adjuvant chemotherapy after LT.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We performed a prospective, multi-center, randomized, non-blinded two-arm trial (pro-duct001). Patients after LT for unresectable PHC within defined criteria were randomized to adjuvant gemcitabine (LT-Gem group) and LT alone (LT alone group). The primary objective was to investigate if adjuvant chemotherapy is feasible in \u2265 85% of patients after LT. The primary endpoint was the percentage of patients completing the 24 weeks course of adjuvant chemotherapy. Secondary endpoints included overall survival (OS) and disease-free (DFS), and complication rates.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twelve patients underwent LT for PHC, of which six (50%) were eligible for randomization (LT-Gem: three patients, LT alone: three patients). Two out of three patients discontinued adjuvant chemotherapy after LT due to intolerance. The study was prematurely terminated due to slow enrollment. One patient with PHC had underlying primary sclerosing cholangitis (PSC). Tumor-free margins could be achieved in all patients. In both the LT-Gem and the LT alone group, the cumulative 1-, 3-, and 5-year OS and DFS rates were 100%, 100%, 67%, and 100%, 67% and 67%, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This prospective, multi-center study was prematurely terminated due to slow enrollment and a statement on the defined endpoints cannot be made. Nevertheless, long-term survival data are consistent with available retrospective data and confirm defined criteria for LT. Since more evidence of LT per se in unresectable PHC is urgently needed, a prospective, non-randomized follow-up study (pro-duct002) has since been launched.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2022.910871","type":"journal-article","created":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T13:10:18Z","timestamp":1665061818000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Feasibility and Efficacy of Adjuvant Chemotherapy With Gemcitabine After Liver Transplantation for Perihilar Cholangiocarcinoma - A Multi-Center, Randomized, Controlled Trial (pro-duct001)"],"prefix":"10.3389","volume":"12","author":[{"given":"Moritz","family":"Schmelzle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Benzing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lutz","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uta","family":"Herden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Sterneck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Utz","family":"Settmacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Astrid","family":"Bauschke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulf","family":"Neumann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uwe","family":"Pelzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Strassburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hauke","family":"Lang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Becker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfred","family":"K\u00f6nigsrainer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvio","family":"Nadalin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Quante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Paul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helmut","family":"Friess","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"Klempnauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Richter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Vondran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Pascher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"R\u00f6sch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenzel","family":"Sch\u00f6ning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Krenzien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"\u00d6llinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Seehofer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Neuhaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johann","family":"Pratschke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s00423-021-02154-4","article-title":"A Tailored Approach in Lymph Node-Positive Perihilar Cholangiocarcinoma","author":"Benzing","year":"2021","journal-title":"Langenbecks Arch Surg"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-011-2077-5","article-title":"Oncological Superiority of Hilar En Bloc Resection for the Treatment of Hilar Cholangiocarcinoma","volume":"19","author":"Neuhaus","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2020.04.068","article-title":"How Long Should Follow-Up be Continued After R0 Resection of Perihilar Cholangiocarcinoma","volume":"168","author":"Nakahashi","year":"2020","journal-title":"Surgery"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-199912000-00010","article-title":"Extended Resections for Hilar Cholangiocarcinoma","volume":"230","author":"Neuhaus","year":"1999","journal-title":"Ann Surg"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: The Next Horizon in Mechanisms and Management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s10353-017-0507-8","article-title":"Hilar En Bloc Resection for Hilar Cholangiocarcinoma in Patients With Limited Liver Capacities-Preserving Parts of Liver Segment 4","volume":"50","author":"Jonas","year":"2018","journal-title":"Eur Surg"},{"key":"B7","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1097\/00000658-200110000-00010","article-title":"Staging, Resectability, and Outcome in 225 Patients With Hilar Cholangiocarcinoma","volume":"234","author":"Jarnagin","year":"2001","journal-title":"Ann Surg"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/lt.20266","article-title":"Transplantation for Hilar Cholangiocarcinoma","volume":"10","author":"Heimbach","year":"2004","journal-title":"Liver Transpl"},{"key":"B9","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1053\/j.gastro.2012.04.008","article-title":"Efficacy of Neoadjuvant Chemoradiation, Followed by Liver Transplantation, for Perihilar Cholangiocarcinoma at 12 US Centers","volume":"143","author":"Darwish Murad","year":"2012","journal-title":"Gastroenterology"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0156127","article-title":"Strict Selection Alone of Patients Undergoing Liver Transplantation for Hilar Cholangiocarcinoma Is Associated With Improved Survival","volume":"11","author":"Mantel","year":"2016","journal-title":"PloS One"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/BF00195875","article-title":"Extended Bile Duct Resection\u2013a New Oncological Approach to the Treatment of Central Bile Duct Carcinomas? Description of Method and Early Results","volume":"379","author":"Neuhaus","year":"1994","journal-title":"Langenbecks Arch Chir"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s005340050168","article-title":"Surgery for Hilar Cholangiocarcinoma\u2013the German Experience","volume":"7","author":"Neuhaus","year":"2000","journal-title":"J Hepatobiliary Pancreat Surg"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s001470050462","article-title":"Orthotopic Liver Transplantation After Extended Bile Duct Resection as Treatment of Hilar Cholangiocarcinoma","author":"Jonas","year":"1998","journal-title":"First long-terms results Transpl Int"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30915-X","article-title":"Capecitabine Compared With Observation in Resected Biliary Tract Cancer (BILCAP): A Randomised, Controlled, Multicentre, Phase 3 Study","volume":"20","author":"Primrose","year":"2019","journal-title":"Lancet Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"12348","DOI":"10.1038\/s41598-020-69366-4","article-title":"High PD-L1 Expression Is Associated With Therapeutic Response to Pembrolizumab in Patients With Advanced Biliary Tract Cancer","volume":"10","author":"Ahn","year":"2020","journal-title":"Sci Rep"},{"key":"B16","article-title":"The 1975 Declaration of Helsinki and Consent","volume":"115","author":"Shephard","year":"1976","journal-title":"Can Med Assoc J"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin Plus Gemcitabine Versus Gemcitabine for Biliary Tract Cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1097\/01.sla.0000133083.54934.ae","article-title":"Classification of Surgical Complications: A New Proposal With Evaluation in a Cohort of 6336 Patients and Results of a Survey","volume":"240","author":"Dindo","year":"2004","journal-title":"Ann Surg"},{"key":"B19","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/hpb.12296","article-title":"Tumour Size Over 3 Cm Predicts Poor Short-Term Outcomes After Major Liver Resection for Hilar Cholangiocarcinoma","volume":"17","author":"Regimbeau","year":"2015","journal-title":"By HC-AFC-2009 Group HPB"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1655775","article-title":"Emerging Technologies for the Diagnosis of Perihilar Cholangiocarcinoma","volume":"38","author":"Rizvi","year":"2018","journal-title":"Semin Liver Dis"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000253551.43583.d1","article-title":"Predictors of Disease Recurrence Following Neoadjuvant Chemoradiotherapy and Liver Transplantation for Unresectable Perihilar Cholangiocarcinoma","volume":"82","author":"Heimbach","year":"2006","journal-title":"Transplantation"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12072","article-title":"Is Post-Transplant Chemotherapy Feasible in Liver Transplantation for Colorectal Cancer Liver Metastases","volume":"40","author":"Brandi","year":"2020","journal-title":"Cancer Commun"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S1499-3872(15)60373-3","article-title":"Adjuvant Chemotherapy After Liver Transplantation for Hepatocellular Carcinoma: A Systematic Review and a Meta-Analysis","volume":"14","author":"Lin","year":"2015","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.12041","article-title":"Cancer in Liver Transplant Recipients: Management and Outcomes","volume":"9","author":"Martin","year":"2013","journal-title":"Asia Pac J Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000000786","article-title":"Chemotherapy or Liver Transplantation for Nonresectable Liver Metastases From Colorectal Cancer","volume":"261","author":"Dueland","year":"2015","journal-title":"Ann Surg"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000003404","article-title":"Survival Following Liver Transplantation for Patients With Nonresectable Liver-Only Colorectal Metastases","volume":"271","author":"Dueland","year":"2020","journal-title":"Ann Surg"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.841694","article-title":"Liver Transplantation for Intrahepatic Cholangiocarcinoma: What Are New Insights and What Should We Follow","volume":"11","author":"Sun","year":"2021","journal-title":"Front Oncol"},{"key":"B28","article-title":"Richtlinien Zur Organtransplantation Gem. \u00a7 16 TPG","volume-title":"Richtlinien Zur Organtransplantation Gem. \u00a7 16 TPG","year":""}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.910871\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T15:18:54Z","timestamp":1666106334000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.910871\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,6]]},"references-count":28,"alternative-id":["10.3389\/fonc.2022.910871"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.910871","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,6]]},"article-number":"910871"}}